{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T17:39:40Z","timestamp":1775756380266,"version":"3.50.1"},"reference-count":64,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomed Rep"],"DOI":"10.3892\/br.2025.2013","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T10:41:07Z","timestamp":1749638467000},"page":"1-11","source":"Crossref","is-referenced-by-count":2,"title":["Valproic acid exposure alters histone deacetylase mRNA expression profile in oral cancer and premalignant cell lines"],"prefix":"10.3892","volume":"23","author":[{"given":"Ahmed","family":"Al\u2011khafaji","sequence":"first","affiliation":[{"name":"Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool L7 8TX, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasir","family":"Qaddoori","sequence":"additional","affiliation":[{"name":"Department of Biology, College of Science, University of Baghdad, Baghdad 10071, Iraq"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haidar","family":"Alabdei","sequence":"additional","affiliation":[{"name":"Scientific Department, Warith International Cancer Institute, Karbala 56001, Iraq"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydia","family":"Wang","sequence":"additional","affiliation":[{"name":"Centre for Haemato\u2011Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2025,6,11]]},"reference":[{"key":"key20250704084514_b1-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.bjoms.2013.03.014","article-title":"Outcomes of oral squamous cell carcinoma arising from oral epithelial dysplasia: Rationale for monitoring premalignant oral lesions in a multidisciplinary clinic","volume":"51","author":"Ho","year":"2013","journal-title":"Br J Oral Maxillofac Surg"},{"key":"key20250704084514_b2-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2165\/00128071-200102040-00005","article-title":"Oral Cancer. The importance of early diagnosis and treatment","volume":"2","author":"Sciubba","year":"2001","journal-title":"Am J Clin Dermatol"},{"key":"key20250704084514_b3-BR-23-2-02013"},{"issue":"4967","key":"key20250704084514_b4-BR-23-2-02013","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194967","article-title":"Challenges in the early diagnosis of oral cancer, evidence gaps and strategies for improvement: A scoping review of systematic reviews","volume":"14","author":"Gonz\u00e1lez-Moles","year":"2022","journal-title":"Cancers (Basel)"},{"key":"key20250704084514_b5-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.oraloncology.2008.05.016","article-title":"Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management","volume":"45","author":"van der Waal","year":"2009","journal-title":"Oral Oncol"},{"issue":"104550","key":"key20250704084514_b6-BR-23-2-02013","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2019.104550","article-title":"Oral potentially malignant disorders: A comprehensive review on clinical aspects and management","volume":"102","author":"Warnakulasuriya","year":"2020","journal-title":"Oral Oncol"},{"key":"key20250704084514_b7-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.oraloncology.2015.06.015","article-title":"The management of oral epithelial dysplasia: The Liverpool algorithm","volume":"51","author":"Field","year":"2015","journal-title":"Oral Oncol"},{"issue":"15874","key":"key20250704084514_b8-BR-23-2-02013","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-34165-5","article-title":"Predicting malignant progression in clinically high-risk lesions by DNA ploidy analysis and dysplasia grading","volume":"8","author":"Zaini","year":"2018","journal-title":"Sci Rep"},{"key":"key20250704084514_b9-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.3892\/ol.2020.11339","article-title":"Overexpression of HURP mRNA in head and neck carcinoma and association with in vitro response to vinorelbine","volume":"19","author":"Al-Khafaji","year":"2020","journal-title":"Oncol Lett"},{"issue":"42","key":"key20250704084514_b10-BR-23-2-02013","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2020.2112","article-title":"Biomarkers of progression to oral cancer in patients with dysplasia: A systematic review","volume":"13","author":"Rivera","year":"2020","journal-title":"Mol Clin Oncol"},{"key":"key20250704084514_b11-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/jop.12088","article-title":"Is there any benefit in surgery for potentially malignant disorders of the oral cavity?","volume":"43","author":"Balasundaram","year":"2014","journal-title":"J Oral Pathol Med"},{"issue":"e0225682","key":"key20250704084514_b12-BR-23-2-02013","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0225682","article-title":"Recurrence rates after surgical removal of oral leukoplakia-A prospective longitudinal multi-centre study","volume":"14","author":"Sundberg","year":"2019","journal-title":"PLoS One"},{"key":"key20250704084514_b13-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4103\/jomfp.JOMFP_13_19","article-title":"Oral epithelial dysplasia: Classifications and clinical relevance in risk assessment of oral potentially malignant disorders","volume":"23","author":"Ranganathan","year":"2019","journal-title":"J Oral Maxillofac Pathol"},{"issue":"9051854","key":"key20250704084514_b14-BR-23-2-02013","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9051854","article-title":"Chemoprevention of head and neck cancers: Does it have only one face?","volume":"2018","author":"Siemianowicz","year":"2018","journal-title":"Biomed Res Int"},{"key":"key20250704084514_b15-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s12276-020-0382-4","article-title":"A short guide to histone deacetylases including recent progress on class II enzymes","volume":"52","author":"Park","year":"2020","journal-title":"Exp Mol Med"},{"issue":"a018713","key":"key20250704084514_b16-BR-23-2-02013","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a018713","article-title":"Erasers of histone acetylation: The histone deacetylase enzymes","volume":"6","author":"Seto","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"a019521","key":"key20250704084514_b17-BR-23-2-02013","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a019521","article-title":"Histone modifications and cancer","volume":"8","author":"Audia","year":"2016","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"key20250704084514_b18-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"5420","DOI":"10.1038\/sj.onc.1210610","article-title":"Histone deacetylases and cancer","volume":"26","author":"Glozak","year":"2007","journal-title":"Oncogene"},{"issue":"a026831","key":"key20250704084514_b19-BR-23-2-02013","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026831","article-title":"HDACs and HDAC inhibitors in cancer development and therapy","volume":"6","author":"Li","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"123219","key":"key20250704084514_b20-BR-23-2-02013","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.123219","article-title":"Curriculum vitae of HDAC6 in solid tumors","volume":"230","author":"Zheng","year":"2023","journal-title":"Int J Biol Macromol"},{"issue":"5","key":"key20250704084514_b21-BR-23-2-02013","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1127-7","article-title":"Role of HDACs in normal and malignant hematopoiesis","volume":"19","author":"Wang","year":"2020","journal-title":"Mol Cancer"},{"key":"key20250704084514_b22-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/ijc.20395","article-title":"Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients","volume":"112","author":"Osada","year":"2004","journal-title":"Int J Cancer"},{"issue":"e7663","key":"key20250704084514_b23-BR-23-2-02013","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007663","article-title":"Histone deacetylase HDAC1 expression correlates with the progression and prognosis of lung cancer: A meta-analysis","volume":"96","author":"Cao","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"215","key":"key20250704084514_b24-BR-23-2-02013","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-215","article-title":"Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer-overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression","volume":"13","author":"M\u00fcller","year":"2013","journal-title":"BMC Cancer"},{"key":"key20250704084514_b25-BR-23-2-02013","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.24996\/ijs.2025.66.5.8","article-title":"The study of histone deacetylases immunoexpression in relation to regulating vascular endothelial growth factor (VEGF) implicated in malignant progression of colorectal cancer","volume":"66","author":"Qaddoori","year":"2025","journal-title":"Iraqi J Sci"},{"key":"key20250704084514_b26-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"393","DOI":"10.15407\/exp-oncology.2024.04.393","article-title":"The potential role of HDAC1 and HDAC3 Immunoexpression in P53 downregulation and tumor aggressiveness of colon and rectum carcinomas patients","volume":"46","author":"Qaddoori","year":"2025","journal-title":"Exp Oncol"},{"key":"key20250704084514_b27-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11010-016-2690-5","article-title":"Overexpression of HDAC9 promotes oral squamous cell carcinoma growth, regulates cell cycle progression, and inhibits apoptosis","volume":"415","author":"Rastogi","year":"2016","journal-title":"Mol Cell Biochem"},{"key":"key20250704084514_b28-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.oraloncology.2008.08.011","article-title":"Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients","volume":"45","author":"Chang","year":"2009","journal-title":"Oral Oncol"},{"key":"key20250704084514_b29-BR-23-2-02013","first-page":"3578","article-title":"Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously","volume":"9 (10 Pt 1)","author":"Kelly","year":"2003","journal-title":"Clin Cancer Res"},{"key":"key20250704084514_b30-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"key20250704084514_b31-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-Cell lymphoma: Results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J Clin Oncol"},{"key":"key20250704084514_b32-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20250704084514_b33-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1414","key":"key20250704084514_b34-BR-23-2-02013","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int J Mol Sci"},{"key":"key20250704084514_b35-BR-23-2-02013"},{"key":"key20250704084514_b36-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"926","DOI":"10.2174\/1570159X17666181227165722","article-title":"Valproic acid and epilepsy: From molecular mechanisms to clinical evidences","volume":"17","author":"Romoli","year":"2019","journal-title":"Curr Neuropharmacol"},{"key":"key20250704084514_b37-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1158\/0008-5472.can-03-0799","article-title":"Histone deacetylase is a target of valproic acid-mediated cellular differentiation","volume":"64","author":"Gurvich","year":"2004","journal-title":"Cancer Res"},{"key":"key20250704084514_b38-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ctrv.2007.11.003","article-title":"Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors","volume":"34","author":"Duenas-Gonzalez","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"key20250704084514_b39-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.3892\/etm.2016.3907","article-title":"Anticancer effects of valproic acid on oral squamous cell carcinoma via SUMOylation in vivo and in vitro","volume":"12","author":"Sang","year":"2016","journal-title":"Exp Ther Med"},{"key":"key20250704084514_b40-BR-23-2-02013"},{"key":"key20250704084514_b41-BR-23-2-02013"},{"key":"key20250704084514_b42-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1586\/14737140.2014.940329","article-title":"Could valproic acid be an effective anticancer agent? The evidence so far","volume":"14","author":"Brodie","year":"2014","journal-title":"Expert Rev Anticancer Ther"},{"key":"key20250704084514_b43-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1002\/cncr.28479","article-title":"Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer","volume":"120","author":"Kang","year":"2014","journal-title":"Cancer"},{"key":"key20250704084514_b44-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1111\/j.1600-0714.2011.01031.x","article-title":"Histone deacetylase-1 and -2 expression in mobile tongue squamous cell carcinoma: Associations with clinicopathological parameters and patients survival","volume":"40","author":"Theocharis","year":"2011","journal-title":"J Oral Pathol Med"},{"issue":"428","key":"key20250704084514_b45-BR-23-2-02013","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05373-8","article-title":"SAVER: Sodium valproate for the epigenetic reprogramming of high-risk oral epithelial dysplasia-a phase II randomised control trial study protocol","volume":"22","author":"McCarthy","year":"2021","journal-title":"Trials"},{"issue":"197","key":"key20250704084514_b46-BR-23-2-02013","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2024.14330","article-title":"Effect of valproic acid on histone deacetylase expression in oral cancer (Review)","volume":"27","author":"Al-Khafaji","year":"2024","journal-title":"Oncol Lett"},{"key":"key20250704084514_b47-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1158\/1541-7786.MCR-07-0324","article-title":"Histone deacetylase inhibitors: Overview and perspectives","volume":"5","author":"Dokmanovic","year":"2007","journal-title":"Mol Cancer Res"},{"issue":"e1000925","key":"key20250704084514_b48-BR-23-2-02013","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1000925","article-title":"Drug-induced regulation of target expression","volume":"6","author":"Iskar","year":"2010","journal-title":"PLoS Comput Biol"},{"key":"key20250704084514_b49-BR-23-2-02013","first-page":"4757","article-title":"Molecular changes associated with oral dysplasia progression and acquisition of immortality: Potential for its reversal by 5-azacytidine","volume":"62","author":"McGregor","year":"2002","journal-title":"Cancer Res"},{"key":"key20250704084514_b50-BR-23-2-02013","doi-asserted-by":"crossref","first-page":"208","DOI":"10.22317\/jcms.v5i4.658","article-title":"Valproic acid enhances the paclitaxel activity in respiratory tract cancer cells","volume":"4","author":"Al-Khafaji","year":"2019","journal-title":"J Contemp Med Sci"},{"key":"key20250704084514_b51-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2212Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"key20250704084514_b52-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrd1930","article-title":"Epigenetic therapy of cancer: Past, present and future","volume":"5","author":"Yoo","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"e495","key":"key20250704084514_b53-BR-23-2-02013","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.495","article-title":"Epigenetic regulation in cancer","volume":"5","author":"Gu","year":"2024","journal-title":"MedComm (2020)"},{"key":"key20250704084514_b54-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"131","DOI":"10.4161\/epi.1.3.2896","article-title":"The epigenetic modifier, valproic acid, enhances radiation sensitivity","volume":"1","author":"Karagiannis","year":"2006","journal-title":"Epigenetics"},{"issue":"1758835920929589","key":"key20250704084514_b55-BR-23-2-02013","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920929589","article-title":"Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin\/fluoropyrimidine regimens in patients with RAS-mutated metastatic colorectal cancer: The REVOLUTION study protocol","volume":"12","author":"Avallone","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"key20250704084514_b56-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"877","DOI":"10.31557\/APJCP.2022.23.3.877","article-title":"Differential expression of zinc-dependent HDAC subtypes and their involvement in unique pathways associated with carcinogenesis","volume":"23","author":"Ukey","year":"2022","journal-title":"Asian Pac J Cancer Prev"},{"key":"key20250704084514_b57-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1111\/j.1471-4159.2005.03457.x","article-title":"Novel targets for valproic acid: Up-regulation of melatonin receptors and neurotrophic factors in C6 glioma cells","volume":"95","author":"Castro","year":"2005","journal-title":"J Neurochem"},{"key":"key20250704084514_b58-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.neulet.2004.04.087","article-title":"Selective regulation of class I and class II histone deacetylases expression by inhibitors of histone deacetylases in cultured mouse neural cells","volume":"365","author":"Ajamian","year":"2004","journal-title":"Neurosci Lett"},{"key":"key20250704084514_b59-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"406","DOI":"10.4161\/cc.10.3.14712","article-title":"Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis","volume":"10","author":"Jurkin","year":"2011","journal-title":"Cell Cycle"},{"key":"key20250704084514_b60-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1158\/1535-7163.MCT-15-0618","article-title":"Inhibition of Class I Histone Deacetylases 1 and 2 promotes urothelial carcinoma cell death by various mechanisms","volume":"15","author":"Pinkerneil","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"key20250704084514_b61-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.3109\/10428194.2015.1034705","article-title":"Analysis of class I and II histone deacetylase gene expression in human leukemia","volume":"56","author":"Yang","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"key20250704084514_b62-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1158\/1541-7786.MCR-08-0299","article-title":"Specific activity of class II histone deacetylases in human breast cancer cells","volume":"6","author":"Duong","year":"2008","journal-title":"Mol Cancer Res"},{"key":"key20250704084514_b63-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/j.1745-7254.2008.00847.x","article-title":"Valproic acid-mediated transcriptional regulation of human GM3 synthase (hST3Gal V) in SK-N-BE(2)-C human neuroblastoma cells","volume":"29","author":"Kwon","year":"2008","journal-title":"Acta Pharmacol Sin"},{"key":"key20250704084514_b64-BR-23-2-02013","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1158\/1541-7786.MCR-13-0396","article-title":"Genomic analysis of head and neck squamous cell carcinoma cell lines and human tumors: A rational approach to preclinical model selection","volume":"12","author":"Li","year":"2014","journal-title":"Mol Cancer Res"}],"container-title":["Biomedical Reports"],"original-title":[],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T05:45:17Z","timestamp":1751607917000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/br.2025.2013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":64,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,6,11]]}},"URL":"https:\/\/doi.org\/10.3892\/br.2025.2013","relation":{},"ISSN":["2049-9434","2049-9442"],"issn-type":[{"value":"2049-9434","type":"print"},{"value":"2049-9442","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,11]]}}}